<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               12 CLINICAL PHARMACOLOGY<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     12.1 Mechanism of Action<BR>                     <BR>                        Telaprevir is a direct-acting antiviral (DAA) agent against the hepatitis C virus [see<BR>                               Microbiology (12.4)<BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     12.2 Pharmacodynamics<BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 ECG Evaluation<BR>                              <BR>                              The effect of telaprevir 750 and 1875 mg on QTc interval was evaluated in a double-blind, double-dummy, randomized, placebo-, and active-controlled (moxifloxacin 400 mg) four period crossover thorough QT trial in 44 subjects. In the trial with demonstrated ability to detect small effects, the upper bound of the one-sided 95% confidence interval for the largest placebo adjusted, baseline-corrected QTc based on Fridericia correction method (QTcF) was below 10 ms, the threshold for regulatory concern. The dose of 1875 mg is adequate to represent the high exposure clinical scenario.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     12.3	Pharmacokinetics<BR>                     <BR>                        The pharmacokinetic properties of telaprevir have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Following multiple doses of telaprevir (750 mg q8h) in combination with peginterferon alfa and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C, mean (SD) Cmax was 3510 (1280) ng/mL, Cmin was 2030 (930) ng/mL, and AUC8h was 22,300 (8650) ng•hr/mL.<BR>                     <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Absorption and Bioavailability<BR>                              <BR>                              Telaprevir is orally available, most likely absorbed in the small intestine, with no evidence for absorption in the colon. Maximum plasma concentrations after a single dose of telaprevir are generally achieved after 4 to 5 hours. In vitro studies performed with human Caco-2 cells indicated that telaprevir is a substrate of P-glycoprotein (P-gp). Exposure to telaprevir is higher during co-administration of peginterferon alfa and ribavirin than after administration of telaprevir alone.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Effects of Food on Oral Absorption <BR>                              <BR>                              The systemic exposure (AUC) to telaprevir was increased by 237% when telaprevir was administered with a standard fat meal (containing 533 kcal and 21 g fat) compared to when telaprevir was administered under fasting conditions. In addition, the type of meal significantly affects exposure to telaprevir. Relative to fasting, when telaprevir was administered with a low-fat meal (249 kcal, 3.6 g fat) and a high-fat meal (928 kcal, 56 g fat), the systemic exposure (AUC) to telaprevir was increased by approximately 117% and 330%, respectively. Doses of INCIVEK were administered within 30 minutes of completing a meal or snack containing approximately 20 grams of fat in the Phase 3 trials. Therefore, INCIVEK should always be taken with food (not low fat).<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Distribution<BR>                              <BR>                              <BR>                                 In vitro, within a concentration range of 0.1 µM (68 ng per mL) to 20 µM (13600 ng per mL), telaprevir is approximately 59% to 76% bound to plasma proteins. Telaprevir binds primarily to alpha 1-acid glycoprotein and albumin and the binding is concentration dependent, decreasing with increasing concentrations of telaprevir. After oral administration, the typical apparent volume of distribution (Vd/F) was estimated to be 252 L, with an inter-individual variability of 72%.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Metabolism<BR>                              <BR>                              Telaprevir is extensively metabolized in the liver, involving hydrolysis, oxidation, and reduction. Multiple metabolites were detected in feces, plasma, and urine. After repeated-oral administration, the R-diastereomer of telaprevir (30-fold less active), pyrazinoic acid, and a metabolite that underwent reduction at the α-ketoamide bond of telaprevir (not active) were found to be the predominant metabolites of telaprevir. In vitro studies using recombinant human cytochrome P450 (CYP) isoforms indicated that CYP3A4 was the major isoform responsible for CYP-mediated telaprevir metabolism. In vitro studies using recombinant aldo-ketoreductases indicated that these and potentially other reductases are also responsible for the reduction of telaprevir. Other proteolytic enzymes are also involved in the hydrolysis of telaprevir. These non-CYP mediated pathways of metabolism likely play a major role after multiple dosing of telaprevir. <BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Elimination<BR>                              <BR>                              Following administration of a single oral dose of 750 mg 14C-telaprevir in healthy subjects, 90% of total radioactivity was recovered in feces, urine and expired air within 96 hours post-dose. The median recovery of the administered radioactive dose was approximately 82% in the feces, 9% in exhaled air and 1% in urine. The contribution of unchanged 14C-telaprevir and the R-diastereomer of telaprevir towards total radioactivity recovered in feces was 31.9% and 18.8%, respectively. After oral administration, the apparent total clearance (Cl/F) was estimated to be 32.4 L per hour with an inter-individual variability of 27.2%. The mean elimination half-life after single-dose oral administration of telaprevir 750 mg typically ranged from about 4.0 to 4.7 hours. At steady state, the effective half-life is about 9 to 11 hours.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Specific Populations<BR>                              <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Hepatic Impairment<BR>                                    <BR>                                    Steady-state exposure to telaprevir was reduced by 46% in HCV-negative subjects with moderate hepatic impairment (Child-Pugh Class B) compared to healthy subjects. The appropriate dose of INCIVEK in HCV-infected subjects with moderate or severe hepatic impairment has not been determined and therefore INCIVEK is not recommended in these populations.<BR>                                    Steady-state exposure to telaprevir was reduced by 15% in HCV-negative subjects with mild hepatic impairment (Child-Pugh Class A) compared to healthy subjects. Dose modification of INCIVEK is not required when administered to subjects with mild hepatic impairment. In previously treated subjects who had compensated liver disease and were treated with INCIVEK in combination with peginterferon alfa and ribavirin, subjects with cirrhosis had similar PK parameters compared to those without cirrhosis.<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Renal Impairment<BR>                                    <BR>                                    After administration of a single dose of 750 mg to HCV-negative subjects with severe renal impairment (CrCl less than 30 mL per min), the LS means of telaprevir Cmax and AUCinf were increased by 3% and 21%, respectively, compared to healthy subjects.<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Gender<BR>                                    <BR>                                    The effect of subject gender on telaprevir pharmacokinetics was evaluated using population pharmacokinetics of data from clinical trials of telaprevir. No dose adjustments are deemed necessary based on gender.<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Race<BR>                                    <BR>                                    Population pharmacokinetic analysis of telaprevir in HCV-infected subjects indicated that race had no apparent effect on the exposure to telaprevir.<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Geriatric Use<BR>                                    <BR>                                    Population pharmacokinetic analysis in HCV-infected subjects showed that within the age range (19-70 years) investigated (35 subjects 65 years of age and older), subject age did not have a clinically relevant effect on the exposure to telaprevir.<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Pediatric Use<BR>                                    <BR>                                    The pharmacokinetics of INCIVEK in pediatric patients have not been evaluated.<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Drug Interactions<BR>                              <BR>                              <BR>                                 In vitro studies indicated that telaprevir is a substrate and a strong inhibitor of CYP3A and P-gp. In vitro studies indicated that telaprevir is also an inhibitor of OATP1B1 and OATP2B1. No inhibition by telaprevir of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP2E1 isozymes was observed in vitro. In vitro studies also suggest that telaprevir does not induce CYP1A, CYP3A, CYP2B6, or CYP2C. Furthermore, in vitro studies suggest that telaprevir is neither a substrate for BCRP, OATP1B1, OATP2B1, or MRP2, nor an inhibitor of BCRP, MRP2, OCT2, and OAT1 transporters. Clinical trials were conducted to evaluate the effect of drugs that can affect or be affected by telaprevir during co-administration (Tables 6 and 7).<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="table6"><BR>                                 <caption>Table 6 Drug Interactions: Summary of Pharmacokinetic Parameters for Telaprevir in the Presence of Co-administered Drugs<footnote ID="table6d">Data provided are under fed conditions unless otherwise noted.</footnote><BR>                                 </caption><BR>                                 <col width="17%" align="left" valign="top"/><BR>                                 <col width="17%" align="left" valign="top"/><BR>                                 <col width="16%" align="left" valign="top"/><BR>                                 <col width="8%" align="center" valign="top"/><BR>                                 <col width="12%" align="center" valign="top"/><BR>                                 <col width="9%" align="center" valign="top"/><BR>                                 <col width="12%" align="center" valign="top"/><BR>                                 <col width="9%" align="center" valign="top"/><BR>                                 <thead><BR>                                    <tr styleCode="Botrule"><BR>                                       <th styleCode="Lrule Rrule" rowspan="2" valign="bottom">Drug</th><BR>                                       <th styleCode="Rrule" colspan="2" valign="bottom" align="center">Dose and Schedule</th><BR>                                       <th styleCode="Rrule" rowspan="2" valign="bottom">N</th><BR>                                       <th styleCode="Rrule" rowspan="2" valign="bottom">Effect on Telaprevir PK<footnote ID="table6a">The direction of the arrow (&#8593; <content styleCode="italics">= increase,</content> &#8595; <content styleCode="italics">= decrease,</content> &#8596; <content styleCode="italics">= no change</content>) indicates the direction of the change in PK</footnote><BR>                                       </th><BR>                                       <th styleCode="Rrule" colspan="3" valign="bottom">LS Mean Ratio (90% CI) of Telaprevir PK With/Without Co-administered Drug</th><BR>                                    </tr><BR>                                    <tr><BR>                                       <th styleCode="Lrule Rrule" align="center" valign="bottom">Drug</th><BR>                                       <th styleCode="Rrule" align="center" valign="bottom">Telaprevir</th><BR>                                       <th styleCode="Rrule" align="center" valign="bottom">C<sub>max</sub><BR>                                       </th><BR>                                       <th styleCode="Rrule" valign="bottom">AUC or C<sub>avg,ss</sub><BR>                                          <footnote ID="table6b">C<sub>avg,ss</sub> = Average concentrations at steady state (AUC<sub>&#964;</sub>/&#964;).</footnote><BR>                                       </th><BR>                                       <th styleCode="Rrule" valign="bottom">C<sub>min</sub><BR>                                       </th><BR>                                    </tr><BR>                                 </thead><BR>                                 <tfoot><BR>                                    <tr><BR>                                       <td colspan="8" align="left">NA: not available/ not applicable; N = Number of subjects with data; qd = once daily; bid = twice daily; q8h = every 8 hours; q12h = every 12 hours</td><BR>                                    </tr><BR>                                 </tfoot><BR>                                 <tbody><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Escitalopram</td><BR>                                       <td styleCode="Rrule">10 mg qd for 7 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 14 days</td><BR>                                       <td styleCode="Rrule">13</td><BR>                                       <td styleCode="Rrule">&#8596;</td><BR>                                       <td styleCode="Rrule">1.00<br/>(0.95; 1.05)</td><BR>                                       <td styleCode="Rrule">0.93<br/>(0.89; 0.97)</td><BR>                                       <td styleCode="Rrule">0.91<br/>(0.86; 0.97)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Esomeprazole</td><BR>                                       <td styleCode="Rrule">40 mg qd for 6 days</td><BR>                                       <td styleCode="Rrule">750 mg single dose</td><BR>                                       <td styleCode="Rrule">24</td><BR>                                       <td styleCode="Rrule">&#8596;</td><BR>                                       <td styleCode="Rrule">0.95<br/>(0.86; 1.06)</td><BR>                                       <td styleCode="Rrule">0.98<br/>(0.91; 1.05)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Ketoconazole</td><BR>                                       <td styleCode="Rrule">Ketoconazole<br/>400 mg single dose</td><BR>                                       <td styleCode="Rrule">750 mg single dose</td><BR>                                       <td styleCode="Rrule">17</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.24<br/>(1.10; 1.41)</td><BR>                                       <td styleCode="Rrule">1.62<br/>(1.45; 1.81)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Oral Contraceptive</td><BR>                                       <td styleCode="Rrule">Norethindrone/ ethinyl estradiol 0.5 mg/0.035 mg qd for 21 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 21 days</td><BR>                                       <td styleCode="Rrule">23</td><BR>                                       <td styleCode="Rrule">&#8596;</td><BR>                                       <td styleCode="Rrule">1.00<br/>(0.93; 1.07)</td><BR>                                       <td styleCode="Rrule">0.99<br/>(0.93; 1.05)</td><BR>                                       <td styleCode="Rrule">1.00<br/>(0.93; 1.08)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Rifampin</td><BR>                                       <td styleCode="Rrule">600 mg qd for 8 days</td><BR>                                       <td styleCode="Rrule">750 mg single dose</td><BR>                                       <td styleCode="Rrule">16</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.14<br/>(0.11; 0.18)</td><BR>                                       <td styleCode="Rrule">0.08<br/>(0.07; 0.11)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" colspan="8"><BR>                                          <content styleCode="bold">Anti-HIV Drugs</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Atazanavir (ATV)/ritonavir (rtv)</td><BR>                                       <td styleCode="Rrule">300 mg ATV/ 100 mg rtv qd for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">14</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.79<br/>(0.74; 0.84)</td><BR>                                       <td styleCode="Rrule">0.80<br/>(0.76; 0.85)</td><BR>                                       <td styleCode="Rrule">0.85<br/>(0.75; 0.98)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Darunavir (DRV)/ritonavir (rtv)</td><BR>                                       <td styleCode="Rrule">600 mg DRV/ 100 mg rtv bid for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">11 (N=14 for C<sub>max</sub>)</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.64<br/>(0.61; 0.67)</td><BR>                                       <td styleCode="Rrule">0.65<br/>(0.61; 0.69)</td><BR>                                       <td styleCode="Rrule">0.68<br/>(0.63; 0.74)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Efavirenz</td><BR>                                       <td styleCode="Rrule">600 mg qd for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">21</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.91<br/>(0.82; 1.02)</td><BR>                                       <td styleCode="Rrule">0.74<br/>(0.65; 0.84)</td><BR>                                       <td styleCode="Rrule">0.53<br/>(0.44; 0.65)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Fosamprenavir (fAPV)/ ritonavir (rtv)</td><BR>                                       <td styleCode="Rrule">700 mg fAPV/ 100 mg rtv bid for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">18</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.67<br/>(0.63; 0.71)</td><BR>                                       <td styleCode="Rrule">0.68<br/>(0.63; 0.72)</td><BR>                                       <td styleCode="Rrule">0.70<br/>(0.64; 0.77)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Lopinavir (LPV)/ritonavir (rtv)</td><BR>                                       <td styleCode="Rrule">400 mg LPV/ 100 mg rtv bid for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">12</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.47<br/>(0.41; 0.52)</td><BR>                                       <td styleCode="Rrule">0.46<br/>(0.41; 0.52)</td><BR>                                       <td styleCode="Rrule">0.48<br/>(0.40; 0.56)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Raltegravir</td><BR>                                       <td styleCode="Rrule">400 mg bid for 11 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">20</td><BR>                                       <td styleCode="Rrule">&#8596;</td><BR>                                       <td styleCode="Rrule">1.07<br/>(0.98; 1.16)</td><BR>                                       <td styleCode="Rrule">1.07<br/>(1.00; 1.15)</td><BR>                                       <td styleCode="Rrule">1.14<br/>(1.04; 1.26)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Ritonavir</td><BR>                                       <td styleCode="Rrule">100 mg single dose</td><BR>                                       <td styleCode="Rrule">750 mg single dose</td><BR>                                       <td styleCode="Rrule">14</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.30<br/>(1.15; 1.47)</td><BR>                                       <td styleCode="Rrule">2.00<br/>(1.72; 2.33)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Ritonavir</td><BR>                                       <td styleCode="Rrule">100 mg q12h for 14 days</td><BR>                                       <td styleCode="Rrule">750 mg q12h for 14 days</td><BR>                                       <td styleCode="Rrule">5</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.85<br/>(0.63; 1.13)</td><BR>                                       <td styleCode="Rrule">0.76<sup>b,c</sup><BR>                                          <br/>(0.60; 0.97)</td><BR>                                       <td styleCode="Rrule">0.68<br/>(0.57; 0.82)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Tenofovir disoproxil fumarate (TDF)</td><BR>                                       <td styleCode="Rrule">300 mg qd TDF for 7 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">16</td><BR>                                       <td styleCode="Rrule">&#8596;</td><BR>                                       <td styleCode="Rrule">1.01<br/>(0.96; 1.05)</td><BR>                                       <td styleCode="Rrule">1.00<br/>(0.94; 1.07)</td><BR>                                       <td styleCode="Rrule">1.03<br/>(0.93; 1.14)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="2">Tenofovir disoproxil fumarate (TDF) and efavirenz (EFV)</td><BR>                                       <td styleCode="Rrule">600 mg EFV /300 mg TDF qd for 7 days</td><BR>                                       <td styleCode="Rrule">1125 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">15</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.86<footnote ID="table6c">Value with co-administered drug and telaprevir / value with telaprevir 750 mg q8h alone</footnote><BR>                                          <br/>(0.76; 0.97)</td><BR>                                       <td styleCode="Rrule">0.82<footnoteRef IDREF="table6c"/><BR>                                          <br/>(0.73; 0.92)</td><BR>                                       <td styleCode="Rrule">0.75<footnoteRef IDREF="table6c"/><BR>                                          <br/>(0.66; 0.86)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">600 mg EFV /300 mg TDF qd for 7 days</td><BR>                                       <td styleCode="Rrule">1500 mg q12h for 7 days</td><BR>                                       <td styleCode="Rrule" align="center">16</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.97<footnoteRef IDREF="table6c"/><BR>                                          <br/>(0.88; 1.06)</td><BR>                                       <td styleCode="Rrule">0.80<footnoteRef IDREF="table6b"/><BR>                                          <sup>,</sup><BR>                                          <footnoteRef IDREF="table6c"/><BR>                                          <br/>(0.73; 0.88)</td><BR>                                       <td styleCode="Rrule">0.52<footnoteRef IDREF="table6c"/><BR>                                          <br/>(0.42; 0.64)</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                              <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="table7"><BR>                                 <caption>Table 7 Drug Interactions: Summary of Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Telaprevir</caption><BR>                                 <col width="17%" align="left" valign="top"/><BR>                                 <col width="17%" align="left" valign="top"/><BR>                                 <col width="16%" align="left" valign="top"/><BR>                                 <col width="8%" align="center" valign="top"/><BR>                                 <col width="9%" align="center" valign="top"/><BR>                                 <col width="12%" align="center" valign="top"/><BR>                                 <col width="12%" align="center" valign="top"/><BR>                                 <col width="9%" align="center" valign="top"/><BR>                                 <thead><BR>                                    <tr styleCode="Botrule"><BR>                                       <th styleCode="Lrule Rrule" rowspan="2" valign="bottom">Drug</th><BR>                                       <th styleCode="Rrule" colspan="2" valign="bottom" align="center">Dose and Schedule</th><BR>                                       <th styleCode="Rrule" rowspan="2" valign="bottom">N</th><BR>                                       <th styleCode="Rrule" rowspan="2" valign="bottom">Effect on Drug PK<footnote ID="table7a">The direction of the arrow (&#8593; <content styleCode="italics">= increase,</content> &#8595; <content styleCode="italics">= decrease,</content> &#8596; <content styleCode="italics">= no change</content>) indicates the direction of the change in PK.</footnote><BR>                                       </th><BR>                                       <th styleCode="Rrule" colspan="3" valign="bottom">LS Mean Ratio (90% CI) of Drug PK With/Without Telaprevir</th><BR>                                    </tr><BR>                                    <tr><BR>                                       <th styleCode="Lrule Rrule" valign="bottom" align="center">Drug</th><BR>                                       <th styleCode="Rrule" valign="bottom" align="center">Telaprevir</th><BR>                                       <th styleCode="Rrule" valign="bottom" align="center">C<sub>max</sub><BR>                                       </th><BR>                                       <th styleCode="Rrule" valign="bottom">AUC</th><BR>                                       <th styleCode="Rrule" valign="bottom">C<sub>min</sub><BR>                                       </th><BR>                                    </tr><BR>                                 </thead><BR>                                 <tbody><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Alprazolam</td><BR>                                       <td styleCode="Rrule">0.5 mg single dose</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">17</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">0.97<br/>(0.92; 1.03)</td><BR>                                       <td styleCode="Rrule">1.35<br/>(1.23; 1.49)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Amlodipine</td><BR>                                       <td styleCode="Rrule">5 mg single dose</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">19</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.27<br/>(1.21; 1.33)</td><BR>                                       <td styleCode="Rrule">2.79<br/>(2.58; 3.01)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Atorvastatin</td><BR>                                       <td styleCode="Rrule">20 mg single dose</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">19</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">10.60<br/>(8.74; 12.85)</td><BR>                                       <td styleCode="Rrule">7.88<br/>(6.84; 9.07)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Buprenorphine</td><BR>                                       <td styleCode="Rrule">Buprenorphine maintenance therapy (4 to 24 mg/daily in combination with naloxone)</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">14</td><BR>                                       <td styleCode="Rrule">&#8596;</td><BR>                                       <td styleCode="Rrule">0.80<br/>(0.69; 0.93)</td><BR>                                       <td styleCode="Rrule">0.96<br/>(0.84; 1.10)</td><BR>                                       <td styleCode="Rrule">1.06<br/>(0.87; 1.30)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Cyclosporine A (CsA)</td><BR>                                       <td styleCode="Rrule">100 mg single dose when administered alone; 10 mg single dose when co-administered with telaprevir (D8)</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 11 days</td><BR>                                       <td styleCode="Rrule">9</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">0.13<br/>(0.11; 0.16)<br/><BR>                                          <content styleCode="bold">Dose norm.: </content>1.32<br/>(1.08; 1.60)</td><BR>                                       <td styleCode="Rrule">0.46<br/>(0.39; 0.55)<br/><BR>                                          <content styleCode="bold">Dose norm.: </content>4.64<br/>(3.90; 5.51)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Digoxin</td><BR>                                       <td styleCode="Rrule">0.5 mg single dose</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 11 days</td><BR>                                       <td styleCode="Rrule">20</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.50<br/>(1.36; 1.65)</td><BR>                                       <td styleCode="Rrule">1.85<br/>(1.70; 2.00)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Escitalopram</td><BR>                                       <td styleCode="Rrule">10 mg qd, for 7 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 14 days<br/><BR>                                       </td><BR>                                       <td styleCode="Rrule">13</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.70<br/>(0.65; 0.76)</td><BR>                                       <td styleCode="Rrule">0.65<br/>(0.60; 0.70)</td><BR>                                       <td styleCode="Rrule">0.58<br/>(0.52; 0.64)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Ethinyl estradiol (EE), co-administered with norethindrone (NE)</td><BR>                                       <td styleCode="Rrule">0.035 mg qd EE/ 0.5 mg<br/>qd NE for 21 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 21 days</td><BR>                                       <td styleCode="Rrule">24</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.74<br/>(0.68; 0.80)</td><BR>                                       <td styleCode="Rrule">0.72<br/>(0.69; 0.75)</td><BR>                                       <td styleCode="Rrule">0.67<br/>(0.63; 0.71)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="2">Ketoconazole</td><BR>                                       <td styleCode="Rrule">400 mg single dose</td><BR>                                       <td styleCode="Rrule">1250 mg q8h for 4 doses</td><BR>                                       <td styleCode="Rrule">81</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.23<br/>(1.14; 1.33)</td><BR>                                       <td styleCode="Rrule">1.46<br/>(1.35; 1.58)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">200 mg single dose</td><BR>                                       <td styleCode="Rrule">1250 mg q8h for 4 doses</td><BR>                                       <td styleCode="Rrule" align="center">28</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.75<br/>(1.51; 2.03)</td><BR>                                       <td styleCode="Rrule">2.25<br/>(1.93; 2.61)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule"><BR>                                          <content styleCode="italics">R-</content>Methadone</td><BR>                                       <td styleCode="Rrule">Methadone maintenance therapy (40 to 120 mg/daily)</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">15</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.71<br/>(0.66; 0.76)</td><BR>                                       <td styleCode="Rrule">0.71<br/>(0.66; 0.76)</td><BR>                                       <td styleCode="Rrule">0.69<br/>(0.64; 0.75)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule"><BR>                                          <content styleCode="italics">S-</content>Methadone</td><BR>                                       <td styleCode="Rrule">Methadone maintenance therapy (40 to 120 mg/daily)</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">15</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.65<br/>(0.60; 0.71)</td><BR>                                       <td styleCode="Rrule">0.64<br/>(0.58; 0.70)</td><BR>                                       <td styleCode="Rrule">0.60<br/>(0.54; 0.67)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Midazolam (iv)</td><BR>                                       <td styleCode="Rrule">0.5 mg iv single dose</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 9 days</td><BR>                                       <td styleCode="Rrule">22</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.02<br/>(0.8; 1.31)</td><BR>                                       <td styleCode="Rrule">3.40<br/>(3.04; 3.79)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Midazolam (oral)</td><BR>                                       <td styleCode="Rrule">2 mg oral single dose</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 11 days</td><BR>                                       <td styleCode="Rrule">21</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">2.86<br/>(2.52; 3.25)</td><BR>                                       <td styleCode="Rrule">8.96<br/>(7.75; 10.35)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Norethindrone (NE), co-administered with EE</td><BR>                                       <td styleCode="Rrule">0.035 mg qd EE/ 0.5 mg<br/>qd NE for 21 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 21 days</td><BR>                                       <td styleCode="Rrule">24</td><BR>                                       <td styleCode="Rrule">&#8596;</td><BR>                                       <td styleCode="Rrule">0.85<br/>(0.81; 0.89)</td><BR>                                       <td styleCode="Rrule">0.89<br/>(0.86; 0.93)</td><BR>                                       <td styleCode="Rrule">0.94<br/>(0.87; 1.0)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Tacrolimus</td><BR>                                       <td styleCode="Rrule">2 mg single dose when administered alone; 0.5 mg single dose when co-administered with telaprevir (D8)</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 13 days</td><BR>                                       <td styleCode="Rrule">9</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">2.34<br/>(1.68; 3.25)<br/><BR>                                          <content styleCode="bold">Dose norm.: </content>9.35<br/>(6.73; 13.0)</td><BR>                                       <td styleCode="Rrule">17.6<br/>(13.2; 23.3)<br/><BR>                                          <content styleCode="bold">Dose norm.: </content>70.3<br/>(52.9; 93.4)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Zolpidem</td><BR>                                       <td styleCode="Rrule">5 mg single dose</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">19</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.58<br/>(0.52; 0.66)</td><BR>                                       <td styleCode="Rrule">0.53<br/>(0.45; 0.64)</td><BR>                                       <td styleCode="Rrule">NA</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" colspan="8"><BR>                                          <content styleCode="bold">Anti-HIV Drugs</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Atazanavir (ATV), boosted with ritonavir (rtv)</td><BR>                                       <td styleCode="Rrule">300 mg ATV/ 100 mg rtv qd for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">7</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">0.85<br/>(0.73; 0.98)</td><BR>                                       <td styleCode="Rrule">1.17<br/>(0.97; 1.43)</td><BR>                                       <td styleCode="Rrule">1.85<br/>(1.40; 2.44)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="2">Darunavir (DRV), boosted with ritonavir (rtv)</td><BR>                                       <td styleCode="Rrule">600 mg DRV/ 100 mg rtv bid for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">11 (N=14 for C<sub>max</sub>)</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.60<br/>(0.56; 0.64)</td><BR>                                       <td styleCode="Rrule">0.60<br/>(0.57; 0.63)</td><BR>                                       <td styleCode="Rrule">0.58<br/>(0.52; 0.64)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">600 mg DRV/ 100 mg rtv bid for 24 days</td><BR>                                       <td styleCode="Rrule">1125 mg q12h for 4 days</td><BR>                                       <td styleCode="Rrule" align="center">15</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.53<br/>(0.47; 0.59)</td><BR>                                       <td styleCode="Rrule">0.49<br/>(0.43; 0.55)</td><BR>                                       <td styleCode="Rrule">0.42<br/>(0.35; 0.51)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Efavirenz</td><BR>                                       <td styleCode="Rrule">600 mg qd for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">21</td><BR>                                       <td styleCode="Rrule">&#8596;</td><BR>                                       <td styleCode="Rrule">0.84<br/>(0.76; 0.93)</td><BR>                                       <td styleCode="Rrule">0.93<br/>(0.87; 0.98)</td><BR>                                       <td styleCode="Rrule">0.98<br/>(0.94; 1.02)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="2">Efavirenz (EFV), co-administered with tenofovir disoproxil fumarate (TDF)</td><BR>                                       <td styleCode="Rrule">600 mg EFV /300 mg TDF qd for 7 days</td><BR>                                       <td styleCode="Rrule">1125 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">15</td><BR>                                       <td styleCode="Rrule">&#8595;<br/><BR>                                       </td><BR>                                       <td styleCode="Rrule">0.76<br/>(0.68; 0.85)</td><BR>                                       <td styleCode="Rrule">0.82<br/>(0.74; 0.90)</td><BR>                                       <td styleCode="Rrule">0.90<br/>(0.81; 1.01)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">600 mg EFV /300 mg TDF qd for 7 days</td><BR>                                       <td styleCode="Rrule">1500 mg q12h for 7 days</td><BR>                                       <td styleCode="Rrule" align="center">16</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.80<br/>(0.74; 0.86)</td><BR>                                       <td styleCode="Rrule">0.85<br/>(0.79; 0.91)</td><BR>                                       <td styleCode="Rrule">0.89<br/>(0.82; 0.96)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="2">Fosamprenavir (fAPV), boosted with ritonavir (rtv)</td><BR>                                       <td styleCode="Rrule">700 mg fAPV/ 100 mg bid rtv for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">18</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.65<br/>(0.59; 0.70)</td><BR>                                       <td styleCode="Rrule">0.53<br/>(0.49; 0.58)</td><BR>                                       <td styleCode="Rrule">0.44<br/>(0.40; 0.50)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Rrule">700 mg fAPV/ 100 mg bid rtv for 24 days</td><BR>                                       <td styleCode="Rrule">1125 mg q12h for 4 days</td><BR>                                       <td styleCode="Rrule" align="center">17 (N=18 for C<sub>min</sub>)</td><BR>                                       <td styleCode="Rrule">&#8595;</td><BR>                                       <td styleCode="Rrule">0.60<br/>(0.55; 0.67)</td><BR>                                       <td styleCode="Rrule">0.51<br/>(0.47; 0.55)</td><BR>                                       <td styleCode="Rrule">0.42<br/>(0.37; 0.47)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Lopinavir (LPV), boosted with ritonavir (rtv)</td><BR>                                       <td styleCode="Rrule">400 mg LPV/ 100 mg rtv bid for 20 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 10 days</td><BR>                                       <td styleCode="Rrule">12</td><BR>                                       <td styleCode="Rrule">&#8596;<br/><BR>                                       </td><BR>                                       <td styleCode="Rrule">0.96<br/>(0.87; 1.05)</td><BR>                                       <td styleCode="Rrule">1.06<br/>(0.96; 1.17)</td><BR>                                       <td styleCode="Rrule">1.14<br/>(0.96; 1.36)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Raltegravir</td><BR>                                       <td styleCode="Rrule">400 mg bid for 11 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">20</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.26<br/>(0.97; 1.62)</td><BR>                                       <td styleCode="Rrule">1.31<br/>(1.03; 1.67)</td><BR>                                       <td styleCode="Rrule">1.78<br/>(1.26; 2.53)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule">Tenofovir disoproxil fumarate</td><BR>                                       <td styleCode="Rrule">300 mg qd for 7 days</td><BR>                                       <td styleCode="Rrule">750 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">16</td><BR>                                       <td styleCode="Rrule">&#8593;</td><BR>                                       <td styleCode="Rrule">1.30<br/>(1.16; 1.45)</td><BR>                                       <td styleCode="Rrule">1.30<br/>(1.22; 1.39)</td><BR>                                       <td styleCode="Rrule">1.41<br/>(1.29; 1.54)</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td styleCode="Lrule Rrule" rowspan="2">Tenofovir, on co-administration of tenofovir disoproxil fumarate (TDF) and efavirenz (EFV)</td><BR>                                       <td styleCode="Rrule">600 mg EFV /300 mg TDF qd for 7 days</td><BR>                                       <td styleCode="Rrule">1125 mg q8h for 7 days</td><BR>                                       <td styleCode="Rrule">15</td><BR>                                       <td styleCode="Rrule">&#8593;<br/><BR>                                       </td><BR>                                       <td styleCode="Rrule">1.22<br/>(1.12; 1.33)</td><BR>                                       <td styleCode="Rrule">1.10<br/>(1.03; 1.18)</td><BR>                                       <td styleCode="Rrule">1.17<br/>(1.06; 1.28)</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td styleCode="Rrule">600 mg EFV /300 mg TDF qd for 7 days</td><BR>                                       <td styleCode="Rrule">1500 mg q12h for 7 days</td><BR>                                       <td styleCode="Rrule" align="center">16</td><BR>                                       <td styleCode="Rrule">&#8593;<br/><BR>                                       </td><BR>                                       <td styleCode="Rrule">1.24<br/>(1.13; 1.37)</td><BR>                                       <td styleCode="Rrule">1.10<br/>(1.03; 1.17)</td><BR>                                       <td styleCode="Rrule">1.06<br/>(0.98; 1.15)</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                           <BR><BR><BR><BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     12.4 Microbiology<BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Mechanism of Action<BR>                              <BR>                              Telaprevir is an inhibitor of the HCV NS3/4A serine protease, necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS4A, NS4B, NS5A and NS5B proteins and essential for viral replication. In a biochemical assay, telaprevir inhibited the proteolytic activity of the recombinant HCV NS3 protease domain with an IC50 value of 10 nM.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Antiviral Activity in Cell Culture<BR>                              <BR>                              In an HCV subtype 1b replicon assay, the telaprevir EC50 value against wild-type HCV was 354 nM in a 2-day cell culture assay, and in a subtype 1a infectious virus assay, the EC50 value was 280 nM in a 5-day cell culture assay. In biochemical enzymatic assays, the median IC50 values of telaprevir against genotype 2, 3a, and 4a were 16 nM (range 6-32 nM; n=5), 40 nM (range 39-88 nM; n=5), and 130 nM (n=1), respectively, compared to a median IC50 value of 20 nM (range 16-23; n=2) for genotype 1a and 20 nM for genotype 1b (range 13-33; n=4). The presence of 40% human serum reduced the anti-HCV activity of telaprevir by approximately 10-fold. Evaluation of telaprevir in combination with interferon alfa or ribavirin showed no evidence of antagonism in reducing HCV RNA levels in HCV replicon cells.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Resistance<BR>                              <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       In Cell Culture<BR>                                    <BR>                                    HCV genotype 1b replicons with reduced susceptibility to telaprevir have been selected in cell culture and characterized for telaprevir genotypic and phenotypic resistance. Additionally, resistance to telaprevir was evaluated in both biochemical and HCV genotype 1b replicon assays using site-directed mutants and recombinant NS3/4A from telaprevir Phase 2 clinical trials isolates. Variants V36A/M, T54A/S, R155K/T, A156S, R155T+D168N, and V36A+T54A conferred 3- to 25-fold reduced susceptibility to telaprevir; and A156V/T variants and the V36M/A+R155K/T and T54S/A+A156S/T double variants conferred greater than 62-fold reduced susceptibility to telaprevir. No amino acid substitutions were observed at the proteolytic cleavage sites.<BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       In Clinical Trials<BR>                                    <BR>                                    In a pooled analysis of subjects who did not achieve SVR (on-treatment virologic failure or relapse) from the controlled Phase 3 clinical trials, NS3 amino acid substitutions V36M/A/L, T54A/S, R155K/T, and A156S/T were determined to emerge frequently on INCIVEK treatment (Table 8). Nearly all of these substitutions have been shown to reduce telaprevir anti-HCV activity in cell culture or biochemical assays. No clear evidence of treatment-emergent substitutions in the NS3 helicase domain or NS4A coding regions of the HCV genome was observed among subjects treated with INCIVEK who did not achieve SVR.<BR>                                    Telaprevir treatment-emergent resistance substitutions emerged in the majority of isolates from subjects who did not achieve SVR (Table 8): in almost 100% of subjects who failed during 12 weeks of T/PR and in the majority of subjects who failed on PR after Week 12 or who relapsed.<BR>                                    HCV genotype 1 subtype-associated patterns of INCIVEK treatment-emergent amino acid substitutions were observed. Subjects with HCV genotype 1a predominately had V36M and R155K or the combination of these variants, while subjects with HCV genotype 1b predominately had V36A, T54A/S, and A156S/T variants (Table 8). Among subjects treated with telaprevir, on-treatment virologic failure was more frequent in subjects with genotype 1a than with genotype 1b and more frequent in prior null responders [see <BR>                                          Clinical Studies (14)<BR>                                       ].<BR>                                    <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%"><BR>                                       <caption>Table 8: Treatment-Emergent Substitutions in Pooled Phase 3 Trials: Subjects who did not achieve SVR24 in INCIVEK Combination Treatment Arms</caption><BR>                                       <col width="31%" align="center" valign="top"/><BR>                                       <col width="23%" align="center" valign="top"/><BR>                                       <col width="23%" align="center" valign="top"/><BR>                                       <col width="23%" align="center" valign="top"/><BR>                                       <thead><BR>                                          <tr><BR>                                             <th styleCode="Lrule Rrule">Emerging Substitutions<footnote ID="table8a">Alone or in combination with other substitutions (includes mixtures)</footnote> in NS3</th><BR>                                             <th styleCode="Rrule">Percent of No SVR Subjects (n)<br/>N=525</th><BR>                                             <th styleCode="Rrule">Percent Subtype 1a<br/>No SVR Subjects (n)<br/>N=356</th><BR>                                             <th styleCode="Rrule">Percent Subtype 1b<br/>No SVR Subjects (n)<br/>N=169</th><BR>                                          </tr><BR>                                       </thead><BR>                                       <tbody><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">Any substitution at V36, T54, R155, A156 or D168</td><BR>                                             <td styleCode="Rrule">62% (323)</td><BR>                                             <td styleCode="Rrule">69% (247)</td><BR>                                             <td styleCode="Rrule">45% (76)</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">R155K/T</td><BR>                                             <td styleCode="Rrule">38% (201)</td><BR>                                             <td styleCode="Rrule">56% (200)</td><BR>                                             <td styleCode="Rrule">0.6% (1)</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">V36M</td><BR>                                             <td styleCode="Rrule">33% (178)</td><BR>                                             <td styleCode="Rrule">49% (173)</td><BR>                                             <td styleCode="Rrule">3% (5)</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">V36M + R155K<footnote ID="table8b">Subjects with this combination are also encompassed in two V36M and R155K rows above.</footnote><BR>                                             </td><BR>                                             <td styleCode="Rrule">27% (142)</td><BR>                                             <td styleCode="Rrule">40% (142)</td><BR>                                             <td styleCode="Rrule">0% (0)</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">T54A/S</td><BR>                                             <td styleCode="Rrule">13% (68)</td><BR>                                             <td styleCode="Rrule">9% (31)</td><BR>                                             <td styleCode="Rrule">22% (37)</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">V36A/L</td><BR>                                             <td styleCode="Rrule">12% (65)</td><BR>                                             <td styleCode="Rrule">10% (37)</td><BR>                                             <td styleCode="Rrule">17% (28)</td><BR>                                          </tr><BR>                                          <tr styleCode="Botrule"><BR>                                             <td styleCode="Lrule Rrule">A156S/T</td><BR>                                             <td styleCode="Rrule">9% (48)</td><BR>                                             <td styleCode="Rrule">8% (28)</td><BR>                                             <td styleCode="Rrule">12% (20)</td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td styleCode="Lrule Rrule">V36G/I, I132V, R155G/M, A156V/F/N or D168N</td><BR>                                             <td styleCode="Rrule">Less than 2%</td><BR>                                             <td styleCode="Rrule">Less than 2%</td><BR>                                             <td styleCode="Rrule">Less than 2%</td><BR>                                          </tr><BR>                                       </tbody><BR>                                    </table><BR>                                 <BR><BR><BR><BR>                                 <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Persistence of Resistance-Associated Substitutions<BR>                              <BR>                              Persistence of telaprevir-resistant NS3 amino acid substitutions has been observed following treatment failure. Of a combined 255 treatment-naïve and previously treated subjects from Trials 108, 111, and C216 in whom telaprevir-resistant variants had emerged during treatment, 103 (40%) had detectable resistant variants by population sequencing at end of trial (follow-up range 2-70 weeks, median 45 weeks) and results for loss of variants were similar across the 3 trials. In the combined trials, 46% of the telaprevir-resistant substitutions in subtype 1a and 16% of the substitutions in subtype 1b were still detected by the end of trial: 29% of V36, 16% of T54, 38% of R155, 14% of A156, and 44% of V36M+R155K variants were detected at the end of trial.<BR>                              In a 3-year follow-up trial of 56 treatment-naïve and prior treatment-failure subjects who did not achieve SVR with a telaprevir regimen in a Phase 2 trial and had telaprevir-resistant variants after treatment failure, variants were detected by population sequencing in 11% (6/56) of subjects (median follow-up of 25 months). Telaprevir-resistant variants V36L/M, T54S, and R155K were detectable (present at greater than 25% of the viral population) in some subjects at 24 months. By 36 months, V36M, T54A/S, and A156N/S/T variants had fallen below the level of detection by population sequencing in all subjects. At 36 months, 3% of the subject isolates that had the R155K variant still had detectable R155K variants by population sequencing.<BR>                              The lack of detection of a substitution based on a population-based assay does not necessarily indicate the substitution has declined to the pre-treatment level. The long-term clinical impact of the emergence or persistence of detectable INCIVEK resistance-associated substitutions is unknown. No data are available regarding INCIVEK efficacy among patients who were previously exposed to INCIVEK, or who previously failed treatment with a regimen containing INCIVEK.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Effect of Baseline HCV Substitutions/Polymorphisms on Treatment Response<BR>                              <BR>                              A pooled analysis was conducted to explore the association between the detection (population-based assay) of baseline NS3/4A amino acid substitutions/polymorphisms and treatment outcome in Trials 108, 111, and C216. Baseline polymorphisms at NS3 position Q80 (Q80K, Q80L, Q80R), which are frequently observed in HCV genotype 1a-infected subjects and have been reported to reduce the activity of some HCV NS3/4A protease inhibitors, were not associated with reduced INCIVEK efficacy.<BR>                              Telaprevir-associated resistance substitutions (substitutions at positions V36, T54, R155 or D168) were present at baseline in 5% (117/2217) of the available subject samples in the combined clinical trials. Given the small number of subjects with baseline telaprevir resistance substitutions, conclusions about their effect on response outcomes when these substitutions are present at baseline cannot be determined.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Cross-Resistance<BR>                              <BR>                              Treatment-emergent NS3 amino acid substitutions detected in subjects treated with INCIVEK who did not achieve SVR in the clinical trials (substitutions at positions V36, T54, R155, A156 or D168) have been demonstrated to reduce the anti-HCV activity of boceprevir and other HCV NS3/4A protease inhibitors. The impact of prior INCIVEK exposure or treatment failure on the efficacy of boceprevir or other HCV NS3/4A protease inhibitors has not been studied. INCIVEK efficacy has not been established for patients with a history of exposure to NS3/4A protease inhibitors.<BR>                              Cross-resistance is not expected between INCIVEK and interferons, or INCIVEK and ribavirin. HCV replicons expressing telaprevir-associated resistance substitutions remained fully sensitive to interferon-alfa and ribavirin, as well as other direct-acting antivirals with different mechanisms of action, such as NS5B polymerase inhibitors.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     12.5	Pharmacogenomics<BR>                     <BR>                        A genetic variant near the gene encoding interferon-lambda-3 (IL28B rs12979860, a C to T change) is a strong predictor of response to peginterferon alfa and ribavirin (PR). rs12979860 was genotyped in 454 of 1088 subjects in Trial 108 (treatment-naïve) and 527 of 662 subjects in Trial C216 (previously treated) [see<BR>                               Clinical Studies (14.2<BR>                            and<BR>                               14.3) <BR>                           for trial descriptions]. SVR rates tended to be lower in subjects with the CT and TT genotypes compared to those with the CC genotype, particularly among treatment-naïve subjects receiving PR48 (Table 9). Among both treatment-naïve and previous treatment failures, subjects of all IL28B genotypes appeared to have higher SVR rates with regimens containing INCIVEK. The results of this retrospective subgroup analysis should be viewed with caution because of the small sample size and potential differences in demographic or clinical characteristics of the subtrial population relative to the overall trial population.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%"><BR>                           <caption>Table 9: SVR Rates by rs12979860 Genotype</caption><BR>                           <col width="25%" align="left" valign="top"/><BR>                           <col width="25%" align="left" valign="top"/><BR>                           <col width="25%" align="center" valign="top"/><BR>                           <col width="25%" align="center" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule">Trial</th><BR>                                 <th styleCode="Rrule">rs12979860 Genotype</th><BR>                                 <th styleCode="Rrule" colspan="2">SVR, n/N (%)</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule"/><BR>                                 <td styleCode="Lrule"><BR>                                    <content styleCode="bold">T12/PR</content><BR>                                 </td><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Pbo/PR48</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">108 (treatment-na&#239;ve)</content><BR>                                 </td><BR>                                 <td styleCode="Rrule">C/C</td><BR>                                 <td styleCode="Rrule">45/50 (90%)</td><BR>                                 <td styleCode="Rrule">35/55 (64%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule">C/T</td><BR>                                 <td styleCode="Rrule">48/68 (71%)</td><BR>                                 <td styleCode="Rrule">20/80 (25%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule">T/T</td><BR>                                 <td styleCode="Rrule">16/22 (73%)</td><BR>                                 <td styleCode="Rrule">6/26 (23%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"><BR>                                    <content styleCode="bold">T12 /PR48<footnote ID="table9a">Lead-in and immediate start T12/PR regimens pooled.</footnote><BR>                                    </content><BR>                                 </td><BR>                                 <td styleCode="Rrule"><BR>                                    <content styleCode="bold">Pbo/PR48</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">C216 (previously treated)</content><BR>                                 </td><BR>                                 <td styleCode="Rrule">C/C</td><BR>                                 <td styleCode="Rrule">60/76 (79%)</td><BR>                                 <td styleCode="Rrule">5/17 (29%)</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule">C/T</td><BR>                                 <td styleCode="Rrule">160/266 (60%)</td><BR>                                 <td styleCode="Rrule">9/58 (16%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule">T/T</td><BR>                                 <td styleCode="Rrule">49/80 (61%)</td><BR>                                 <td styleCode="Rrule">4/30 (13%)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>